144 ·Filed Jun 25, 2026

DFTX

Definium Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed3mo ago SEC0001950047-26-006493
Form 144 — notice of proposed sale of securities
Actionable Insight • Neutral

This is a routine insider intent-to-sell filing following a vesting event. The dollar amount is immaterial relative to market cap. Monitor for actual sale execution on Form 4; no immediate trading signal.

DirectionNeutral
Confidencemedium
Horizondays
Final — all horizons settled through T+60d ⚠ clustered
DFTX ▼ -12.61% at T+60d
NEUTRAL call ✗ call lost -12.61% · α vs SPY -17.10% · entry $44.95 → $39.28
Entry anchored
Jun 25, 03:59 PM ET
via exchange tick
T+1d
+3.56%
call +3.56% · α +1.91%
$46.55
settled 3mo ago
T+5d
-1.69%
call -1.69% · α -3.86%
$44.19
settled 3mo ago
T+20d
-4.49%
call -4.49% · α -5.75%
$42.93
settled 2mo ago
T+60d
-12.61%
call -12.61% · α -17.10%
$39.28
settled 11d ago

Price Chart

Loading chart...

Executive Summary

Mark Sullivan, an officer of Definium Therapeutics, filed a Form 144 notice of intent to sell 13,008 shares of common stock, with an estimated aggregate market value of approximately $548,027. The shares were acquired through restricted stock vesting under a registered plan on June 25, 2026. This filing signals the insider's intent to sell, though the sale may not be executed.

Key Facts

  • Mark Sullivan, an officer, filed Form 144 to sell 13,008 shares of DFTX common stock.
  • Estimated aggregate market value of the proposed sale is approximately $548,027.
  • Shares were acquired via restricted stock vesting under a registered plan on June 25, 2026.
  • The filing date is June 25, 2026; the proposed sale is intended to occur on or after that date.
  • The sale is for the account of the reporting person (Mark Sullivan) and is not a gift or other transfer.

Financial Impact

Proposed sale of ~$548,027 worth of DFTX common stock, representing a small fraction of the company's $4.6B market cap.

dilutioninsider holdings

Risk Factors

  • Insider sale may signal reduced conviction if executed in large size relative to holdings.
  • Form 144 is only an intent to sell; the sale may not occur.

Market Snapshot

Exchange
Nasdaq
Sector
Medicinal Chemicals & Botanical Products
Analyst Consensus
95% bullish (22 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-006493
Document: 0001950047-26-006493-index.html0001950047-26-006493
Document: 0001950047-26-006493.txt0001950047-26-006493
9 reports for DFTX
Performance horizon
67% Hit rate 4 of 6 directional calls best @ T+60▲ +13.35%Jun 24, 2026
Filters
Rows
Reports for DFTX — sortable, filterable
TypeNow
Sep 14, 2026
18d ago
8-K
BULLISH ★ 8/10
$40.25 $39.28▼ −2.41%▼ −2.52%$37.40 (−7.08%)
Aug 12, 2026
7w ago
8-K
BULLISH ★ 7/10
$42.79 $45.82▲ +7.08%▲ +7.53%$37.40 (−12.60%)
Aug 9, 2026
7w ago
Institutional Cluster
BULLISH ★ 5/10
$45.15 $45.26▲ +0.24%▲ +0.29%$37.40 (−17.17%)
Jun 25, 2026
14w ago
144
NEUTRAL ★ 3/10
$44.95 $44.19▼ −1.69%▼ −3.86%$37.40 (−16.80%)
Jun 25, 2026
14w ago
144
NEUTRAL ★ 2/10
$44.95 $44.19▼ −1.69%▼ −3.86%$37.40 (−16.80%)
Jun 24, 2026
14w ago
8-K
BEARISH ★ 6/10
$44.79 $43.40▲ +3.10%▲ +4.66%$37.40 (+16.50%)
Jun 24, 2026
14w ago
424B5
BEARISH ★ 6/10
$44.79 $43.40▲ +3.10%▲ +4.66%$37.40 (+16.50%)
Jun 22, 2026
14w ago
424B5
BEARISH ★ 7/10
$36.18 $46.55▼ −28.66%▼ −27.65%$37.40 (−3.37%)
Apr 27, 2026
22w ago
DEFA14A
NEUTRAL ★ 2/10
$21.27 $21.75▲ +2.26%▲ +0.56%$37.40 (+75.83%)
Showing 9 of 9

US Market Status

Market Closed — Opens Mon (37h 46m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access